BioSpace News Archive

To help you take on any task you’re given at work, BioSpace has provided a guide detailing what to do when you’re asked to do things above your experience level.

Karuna Therapeutics acquired exclusive rights to Goldfinch Bio’s investigational TRPC4/5 channel candidates in a deal potentially worth $520 million.

Recent scientific papers report errors in CRISPR gene editing linked to ancestry.

Roche is dropping its investigational AKT inhibitor ipatasertib, which was being assessed in a Phase III trial for castration-resistant prostate cancer, as well as several other candidates.

Wednesday, the FDA approved GSK’s daprodustat, now to be marketed as Jesduvroq, for the treatment of anemia due to chronic kidney disease in adult patients.

Patient Square Capital announced a record-breaking inaugural fund totaling $3.9 billion, proving even in an unstable economy, there’s still money to be made.

Ardelyx, Inc. announced that on January 27, 2023, the compensation committee of the company’s board of directors granted 23 new non-executive employees options to purchase an aggregate of 614,064 shares of the company’s common stock, and an aggregate of 236,333 Restricted Stock Units.

enGene, Inc., a clinical-stage biotechnology company pioneering novel non-viral gene therapies for local administration into mucosal tissues enabled by its proprietary DDX platform, today announced that Alex Nichols, PhD, has joined the company as President and Chief Operating Officer.

CONMED Corporation (NYSE: CNMD) today announced financial results for the fourth quarter and full-year ended December 31, 2022.

StageZero Life Sciences, Ltd. (TSX: SZLS) (OTCQB: SZLSF) (“StageZero” or the “Company”), a vertically integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, announced today that its special meeting (the “Meeting”) originally scheduled for Tuesday February 28, will now be combined with the Annual General Meeting (“AGM”) in Q2 2023.